An extensive Phase 3 clinical trial programme

DUPIXENT was studied in six Phase 3 clinical trials, in adults with moderate-to-severe atopic dermatitis (AD) including more than 2,400 adult patients worldwide, both as a monotherapy and with TCS for up to 52 weeks1

DUPIXENT was studied as a monotherapy, in 251 adolescents  with moderate-to-severe AD inadequately controlled with topical treatment for up to 16 weeks 2,3

DUPIXENT was studied with TCS in 367 children with severe AD for up to 16 weeks compared to placebo with TCS 4

DUPIXENT has a long-term safety and tolerability profile investigated up to 3 years in clinical trials in adults, which is consistent with the safety profile in adolescents and children.1


Learn more about how to administer DUPIXENT.

Find out more

Safety Profile

Learn more about safety profile of DUPIXENT.

Find out more

Overview of AD

Find out more about how AD has a continuous inflammation cycle.

Find out more

    AD atopic dermatitis; TCS, topical corticosteroids.


    1. DUPIXENT Summary of Product Characteristics. September 2021.
    2. Paller AS, et al. Dupilumab for Adolescents With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 3, Randomized, Double-Blinded Trial (Poster 10051) presented at the 77th annual meeting of the American Academy of Dermatology, Washington, DC, USA, March 1–5 2019.
    3. Simpson EL, et al. Dupilumab Efficacy and Safety in Adolescents With Moderate-to-Severe Atopic Dermatitis: Results From a Multicenter, Randomized, Placebo Controlled, Double-Blind, Parallel-Group, Phase 3 Study (Poster PA-17) presented at the 43rd annual Hawaii Dermatology Seminar; Waikoloa, HI, USA,
      February 17–22 2019.
    4. Paller AS, et al. Dupilumab Significantly Improves Atopic Dermatitis in Children Aged ≥6 to <12 years: Results From Phase 3 Trial (LIBERTY AD PEDS) (Presentation) presented at the virtual Revolutionizing Atopic Dermatitis Conference, Chicago, IL, USA, April 5th 2020.

MAT-IE-2100181(v4.0) | Date of preparation: February 2022